Skip to main content
. 2020 Jan 30;30(1):21–31. doi: 10.1089/cap.2019.0076

Table 1.

Baseline Characteristics of the Modified Intent-to-Treat Population

Characteristic Placebo
LDX 30 mg
LDX 50 mg
LDX 70 mg
 
(n = 19) (n = 19) (n = 18) (n = 20) p value
Male gender, n (%) 16 (84.2) 16 (84.2) 13 (72.2) 18 (90.0) 0.5576a
Age, years; mean (SD) 9.9 (2.7) 10.1 (3.1) 10.0 (2.9) 10.1 (2.5) 0.9963b
Height, cm; mean (SD) 138.2 (15.5) 139.2 (17.4) 135.0 (13.5) 138.9 (13.7) 0.8183b
Bodyweight, kg; mean (SD) 34.9 (12.3) 38.5 (15.9) 33.1 (11.2) 35.8 (11.7) 0.6416b
Previous medical conditions; n (% pts) 8 (42.1) 2 (10.5) 5 (27.8) 3 (15.0) 0.1091a
Concurrent medical conditions; n (% pts) 14 (73.7) 14 (73.7) 12 (66.7) 17 (85.0) 0.6216a
Previous drug treatment; n (% pts) 6 (31.6) 7 (36.8) 6 (33.3) 5 (25.0) 0.9024a
ADHD subtype; n (% pts)         0.1217a
 Combined 14 (73.7) 10 (52.6) 13 (72.2) 11 (55.0)  
 Predominantly inattentive 3 (15.8) 9 (47.4) 5 (27.8) 9 (45.0)  
 Predominantly hyperactive/impulsive 2 (10.5) 0 (0.0) 0 (0.0) 0 (0.0)  
ADHD-RS-IV total score <40 at baseline; n (% pts) 12 (63.2) 12 (63.2) 12 (66.7) 12 (60.0) 0.9610b
ADHD-RS-IV total score ≥40 at baseline; n (% pts) 7 (36.8) 7 (36.8) 6 (33.3) 8 (40.0)
Baseline ADHD-RS-IV total score; mean (SD) 37.9 (7.4) 38.1 (6.7) 37.1 (6.9) 37.2 (7.8)  
a

Fisher's exact test.

b

One-way analysis of variance.

ADHD, attention-deficit/hyperactivity disorder; LDX, lisdexamfetamine; m-ITT, modified intent-to-treat; pts, patients; SD, standard deviation.